^
BIOMARKER:

IFNG positive signature

News
Twitter
Trials
IFNG positive signature
Bladder Cancer
durvalumab
Sensitive: C3 – Early Trials
IFNG positive signature
NSCLC
durvalumab
Sensitive: C3 – Early Trials